Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | ACR | P10323 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27461707 | 0.85 | MIF (0.41) | TDP1KMT2AMEN1CYP3A4LMNA | |
| SCHEMBL28033164 | 0.83 | KMT2A (0.61) | MAPK1TDP1KMT2AMEN1CYP3A4 | |
| SCHEMBL633251 | 0.81 | KMT2A (0.37) | MAPK1TDP1KMT2AMEN1CYP3A4 | |
| SCHEMBL633675 | 0.80 | MAPK1 (0.36) | MAPK1TDP1KMT2AMEN1CYP3A4 | |
| SCHEMBL633676 | 0.80 | MAPK1 (0.36) | MAPK1TDP1KMT2AMEN1LMNA | |
| SCHEMBL11416323 | 0.80 | ACHE (0.48) | MAPK1CYP3A4LMNAACHENPC1 | |
| SCHEMBL11395483 | 0.80 | KMT2A (0.51) | TDP1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL3320371 | 0.79 | CYP3A4 (0.44) | MAPK1TDP1CYP3A4LMNATRPA1 | |
| SCHEMBL702050 | 0.79 | TDP1 (0.46) | MAPK1TDP1KMT2AMEN1CYP3A4 | |
| SCHEMBL633163 | 0.78 | ELANE (0.43) | MAPK1TDP1KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102351738-A | Method for the reduction of chlorine-containing components in organic isocyanates | LANXESS DEUTSCHLAND GMBH | 2012-02-15 | — | — | CN | claimed |
| CN-101084187-B | Process for reducing chlorine-containing components in organic isocyanates | LANXESS DEUTSCHLAND GMBH | 2011-09-28 | — | — | CN | claimed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| CN-102351738-A | Method for the reduction of chlorine-containing components in organic isocyanates | LANXESS DEUTSCHLAND GMBH | 2012-02-15 | — | — | CN | disclosed |
| CN-101084187-B | Process for reducing chlorine-containing components in organic isocyanates | LANXESS DEUTSCHLAND GMBH | 2011-09-28 | — | — | CN | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-101084187-A | Process for reducing chlorine-containing components in organic isocyanates | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1220683-C | Acyl derivatives for the treatment of VLA-4 related diseases | ELAN PHARM INC (US) | 2005-09-28 | — | — | CN | disclosed |
| CN-1195773-C | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2005-04-06 | — | — | CN | disclosed |
| CN-1185250-C | Compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1133648-C | Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion | ������˹ҩƷ��˾ | 2004-01-07 | — | — | CN | disclosed |
| CN-1351592-A | Acyl derivatives for the treatment of VLA-4 related diseases | ELAN PHARM INC (US) | 2002-05-29 | — | — | CN | disclosed |
| CN-1344274-A | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2002-04-10 | — | — | CN | disclosed |
| CN-1340058-A | Compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2002-03-13 | — | — | CN | disclosed |
| CN-1265674-A | 4-aminophenylalanine compounds for inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1265670-A | Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1265672-A | Sulphonylated dipeptide Compounds capable of inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1265668-A | Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1186505-A | Polydiorganosiloxane oligourea segmented copolymers and process for making same | MINNESODA MINING AND MANUFACTU (US) | 1998-07-01 | — | — | CN | disclosed |